Skip to content

Hydroxyethyl Starch and Renal Function After Hip Replacement Surgery

Effect of Hydroxyethyl Starch on Renal Handling of Sodium and Water, Vasoactive Hormones,Biomarkers and the Circulatory System in Patients Undergoing Hip Replacement Surgery

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01486576
Acronym
VOHO
Enrollment
42
Registered
2011-12-06
Start date
2012-01-31
Completion date
2013-03-31
Last updated
2013-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Brief summary

The purpose of this project is to investigate if hydroxyethyl starch (HES) is potential nephrotoxic and examine the effects on the circulation and kidneys during administration of HES during surgery.

Detailed description

Hydroxyethyl starch (HES) is widely used in hospitals to maintain circulation in critically ill patients. In recent years studies have raised suspicion that HES is nephrotoxic. So far acute kidney injury has been diagnosed based on creatinine measurements, but new technology allows for earlier diagnosis using measurements of biomarkers in urine. The purpose of this project is to investigate HES's potential toxicity and effects on the circulation and kidneys using measurements of biomarkers specific for toxicity and for the sodium/water balance in the urine and by measurements of vasoactive hormones in the blood after administration of HES 130/0.4

Interventions

7,5 ml/kg in the first hour and then 5 ml/kg

7,5 ml/kg in the first hour and then 5 ml/kg

Sponsors

Regional Hospital Holstebro
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 years * Males and females * Indication for Arthroplasty of hip

Exclusion criteria

* Blood donation within the last month * Lack of wish to participate * eGFR\< 15ml/min * pregnancy or breast feeding * Need of NSAID

Design outcomes

Primary

MeasureTime frameDescription
u-NGAL2-4 hoursThe main objective is for the trial (only patients undergoing elective hip replacement surgery) to measure the effect of hydroxyethyl starch on u-NGAL, which is a biomarker of nephrotoxicity

Secondary

MeasureTime frameDescription
u-Kim1, u-LFABP2-4 hoursAnother objective of the trial (only patients undergoing elective hip replacement surgery) to measure the effect of hydroxyethyl starch on u-Kim1 and u-LFABP, which are biomarkers of nephrotoxicity
FENa, u-ENaCβ, CH2O, u-AQP2,u-NCC, u-NK2CC2-4 hoursSecondarily to measure the effect of hydroxyethyl starch on the renal tubular transport of sodium and water during elective hip replacement surgery
PRC, p-Ang-II, p -Aldo, p-ANP,P-GDP, p-AVP, p-Endot2-4 hoursSecondarily to measure the effect of hydroxyethyl starch on vasoactive hormones during elective hip replacement surgery
SBP, DBP, heartrate2-4 hoursSecondarily to measure the effect of hydroxyethyl starch on central hemodynamics during elective hip replacement surgery

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026